12:00 AM
 | 
Apr 08, 2013
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Omni Bio Pharmaceutical preclinical data

In a mouse model of gouty arthritis, Fc-AAT dose-dependently reduced joint swelling, IL-6 and IL-1 beta levels, and cell influx vs. IV immunoglobulin (IVIG), with a significant reduction in joint swelling at the 50 µg Fc-AAT dose (p<0.001). Omni...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >